San Diego – Oct 28th, 2019 China’s NMPA Approves Two Separate INDs On The Same Day For Ansun’s Investigational Biologic Compound DAS181
San Diego – May 28th, 2019 Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection
San Diego – Jan 7, 2019 Ansun Biopharma to Present at Biotech Showcase 2019 in San Francisco
San Diego – Oct 4, 2018 Ansun Biopharma Announces Key Appointments to its Executive Management Team
San Diego – Oct 2, 2018 Ansun Biopharma named “Fierce 15” winners in 2018
San Diego – May 18, 2018 Ansun BioPharma secures $85 million in Series A Financing
San Diego – October 10, 2017 Ansun BioPharma Announces Breakthrough Designation for its Experimental Drug DAS181
San Diego – September 27,2016 Ansun BioPharma Announces Two Publications Showing Inhibitory Effects of DAS181 on Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV)
San Diego – May 9, 2016 – Ansun BioPharma Named Buzz of BIO Winner for the 2016 BIO International Convention
San Diego – December 8, 2015 – Ansun Biopharma announces Potent in-vitro DAS181 Activity against Respiratory Syncytial Virus at 5th Congress of Virology.
San Diego – October 9, 2015 – Ansun Biopharma announces successful treatment with DAS181 in a patient with severe influenza and parainfluenza at ISDA meeting.
San Diego – September 28, 2015 – Ansun Biopharma announced today the publication of a report by researchers at the Centers for Disease Control demonstrating the strong inhibition of Enterovirus68 (EV68) by DAS181.
San Diego – July 7th, 2015 – Ansun Biopharma announced today the publication of the report “Treatment of resistant influenza virus infection in a hospitalized patient with cystic fibrosis with DAS181, a host-directed antiviral” in the peer the reviewed Journal “Antiviral Research.”
San Diego – September 9, 2014 – Ansun BioPharma Announces Late Breaker Oral Presentation at ICAAC on the Clinical Activity of ParaDase™, an Investigational Drug for the Treatment of Severe Parainfluenza Infection.